Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0VHRBL
ADC Name
RC-88
Synonyms
RC 88; RC-88 ADC; RC88
   Click to Show/Hide
Organization
RemeGen Co., Ltd.
Drug Status
Phase 1/2
Indication
In total 7 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 2
Gastric cancer [ICD11:2B72]
Phase 1
Intrahepatic bile ducts cancer [ICD11:2C12]
Phase 1
Lung cancer [ICD11:2C25]
Phase 1
Ovarian cancer [ICD11:2C73]
Phase 1
Pancreatic cancer [ICD11:2C10]
Phase 1
Pleural mesothelioma [ICD11:2C26]
Phase 1
Drug-to-Antibody Ratio
4
Structure
Antibody Name
Undisclosed
Antigen Name
Mesothelin (MSLN)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
Vedotin
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT04175847
Phase 1/2
To evaluate the safety of RC88 for injection in patients with advanced malignant solid tumors, multicenter, open, multi-cohort extension of efficacy and pharmacokinetic characteristics phase 1 /2a clinical study.

   Click to Show/Hide
Undisclosed  NCT04175847
Phase 1/2
To evaluate the safety of RC88 for injection in patients with advanced malignant solid tumors, multicenter, open, multi-cohort extension of efficacy and pharmacokinetic characteristics phase 1 /2a clinical study.

   Click to Show/Hide
Undisclosed  NCT05508334
Phase 1
An open-label, non-randomised, multicentre study to allow continued access to and assess the safety and tolerability of RC88 for patients with advanced solid tumours.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT04175847  Clinical Status Phase 1/2
Clinical Description To evaluate the safety of RC88 for injection in patients with advanced malignant solid tumors, multicenter, open, multi-cohort extension of efficacy and pharmacokinetic characteristics phase 1 /2a clinical study.
Experiment 2 Reporting the Activity Date of This ADC [2]
Patients Enrolled
Patients with malignant pleural mesothelioma and MSLN in advanced malignant solid tumors.
Administration Dosage
Dose of 0.10, 0.50, 1.00, 1.50, 2.00 and 2.50 mg/kg.
Related Clinical Trial
NCT Number NCT04175847  Clinical Status Phase 1/2
Clinical Description To evaluate the safety of RC88 for injection in patients with advanced malignant solid tumors, multicenter, open, multi-cohort extension of efficacy and pharmacokinetic characteristics phase 1 /2a clinical study.
Experiment 3 Reporting the Activity Date of This ADC [3]
Related Clinical Trial
NCT Number NCT05508334  Clinical Status Phase 1
Clinical Description An open-label, non-randomised, multicentre study to allow continued access to and assess the safety and tolerability of RC88 for patients with advanced solid tumours.
References
Ref 1 To Evaluate the Safety of RC88 for Injection in Patients With Advanced Malignant Solid Tumors,Multicenter, Open, Multi-cohort Extension of Efficacy and Pharmacokinetic Characteristics Phase I /IIa Clinical Study, NCT04175847
Ref 2 A new immunochemical strategy for triple-negative breast cancer therapy. Sci Rep. 2021 Jul 21;11(1):14875.
Ref 3 An Open-label, Non-randomised, Multicentre Study to Allow Continued Access to and Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours, NCT05508334

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.